BioSpace News Archive

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc.

Surface Oncology today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors.

Despite a COVID-19 disease diagnosis, hospitalization and severe outcomes from COVID-19 illness in children and young people with childhood-onset rheumatic diseases were not commonly reported, announced the Childhood Arthritis and Rheumatology Research Alliance (CARRA).

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be featured at the 2022 American Academy of Neurology (AAN) annual meeting being held April 2-7 in Seattle, WA and virtually from April 24-26.

Eikon Therapeutics Inc. today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022.

According to Report, the durable medical equipment market size is estimated to reach US$ 377.24 billion by 2030 and expanding growth at a CAGR of 6.3% from 2021 to 2030.

The global digital patient monitoring devices market size was evaluated at USD 80.61 billion in 2021 and is expected to reach USD 451.54 billion by 2030, at a CAGR of 21.1% from 2021-2030.

The global biotechnology reagents & kits market size is set to grow exponentially. It was valued at USD 338billion back in 2021 and is predicted to hit around USD 890 billion by 2030, according to Precedence Research.

Evofem Biosciences, Inc., (Nasdaq: EVFM) today presented data at the Academy of Managed Care Pharmacy (AMCP) annual meeting showing EVO100 (the investigational name for Phexxi®) provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product.

Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — “Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study"— at the American Academy of Neurology’s (AAN) Annual Meeting.